Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients

Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2009-12, Vol.54 (6), p.1072-1080
Hauptverfasser: Raj, Dominic S.C., MD, Carrero, Juan J., PhD, Shah, Vallabh O., PhD, Qureshi, Abdul R., MD, Bárány, Peter, MD, Heimbürger, Olof, MD, Lindholm, Bengt, MD, Ferguson, Jennet, BA, Moseley, Pope L., MD, Stenvinkel, Peter, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1080
container_issue 6
container_start_page 1072
container_title American journal of kidney diseases
container_volume 54
creator Raj, Dominic S.C., MD
Carrero, Juan J., PhD
Shah, Vallabh O., PhD
Qureshi, Abdul R., MD
Bárány, Peter, MD
Heimbürger, Olof, MD
Lindholm, Bengt, MD
Ferguson, Jennet, BA
Moseley, Pope L., MD
Stenvinkel, Peter, MD
description Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting & Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.
doi_str_mv 10.1053/j.ajkd.2009.06.022
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_556042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638609009408</els_id><sourcerecordid>733603362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEokvhD3BAuSAuTfBHYscSqlQtH620iEoFcbS89qQ468TFThbtv8fRRoVy4GDZmnnmnZHfybKXGJUY1fRtV6puZ0qCkCgRKxEhj7IVrgktWEObx9kKEU4KRht2kj2LsUMJpIw9zU6w4JSKqlll32-8m7YO8vV7XOUb2IOLZ_nVMEJwMO3skLOzXA0m_-zDqJwdD_lF74fb_DrAXjkYxvwSem-scodoY36tRpuC8Xn2pFUuwovlPs2-ffzwdX1ZbL58ulpfbApdcz4WHFO-1dToVmjKhICq4qjd1oRzQ0SNiSIV19igSlEiRMM45016YyEMEKHoaVYcdeMvuJu28i7YXoWD9MrKJbRLL5B1zVBFEn9-5FOmB6PTrEG5B2UPM4P9IW_9XhLecFE3SeDNIhD8zwniKHsbNTinBvBTlOljGUpnbkWOpA4-xgDtfReM5Gyg7ORsoJwNlIjJZGAqevX3fH9KFscS8HoBVNTKtUEN2sZ7jhDcCCbqxL07cslQ2FsIMurkjAZjA-hRGm__P8f5P-Xa2cGmjjs4QOz8FIbkq8QyEonkzbxq86YhkUQq1NDfRFbOKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733603362</pqid></control><display><type>article</type><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>SWEPUB Freely available online</source><creator>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</creator><creatorcontrib>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</creatorcontrib><description>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting &amp; Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2009.06.022</identifier><identifier>PMID: 19733948</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Biomarkers - blood ; C-reactive protein (CRP) ; C-Reactive Protein - metabolism ; Emergency and intensive care: renal failure. Dialysis management ; Endotoxin ; Endotoxins - blood ; Female ; Follow-Up Studies ; hemodialysis ; Humans ; Inflammation - blood ; Intensive care medicine ; interleukin 6 (IL-6) ; Interleukin-6 - blood ; Lipopolysaccharide Receptors - blood ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Nephrology ; Nephrology. Urinary tract diseases ; pentraxin 3 ; Predictive Value of Tests ; Prospective Studies ; Protein-Energy Malnutrition - blood ; protein-energy wasting ; Renal Dialysis ; Renal Insufficiency - blood ; Renal Insufficiency - mortality ; Renal Insufficiency - therapy ; Serum Amyloid P-Component - metabolism ; Survival Rate ; Sweden</subject><ispartof>American journal of kidney diseases, 2009-12, Vol.54 (6), p.1072-1080</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2009 National Kidney Foundation, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>2009 The National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638609009408$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22189695$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19733948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:119661937$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Raj, Dominic S.C., MD</creatorcontrib><creatorcontrib>Carrero, Juan J., PhD</creatorcontrib><creatorcontrib>Shah, Vallabh O., PhD</creatorcontrib><creatorcontrib>Qureshi, Abdul R., MD</creatorcontrib><creatorcontrib>Bárány, Peter, MD</creatorcontrib><creatorcontrib>Heimbürger, Olof, MD</creatorcontrib><creatorcontrib>Lindholm, Bengt, MD</creatorcontrib><creatorcontrib>Ferguson, Jennet, BA</creatorcontrib><creatorcontrib>Moseley, Pope L., MD</creatorcontrib><creatorcontrib>Stenvinkel, Peter, MD</creatorcontrib><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting &amp; Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>C-reactive protein (CRP)</subject><subject>C-Reactive Protein - metabolism</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Endotoxin</subject><subject>Endotoxins - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>hemodialysis</subject><subject>Humans</subject><subject>Inflammation - blood</subject><subject>Intensive care medicine</subject><subject>interleukin 6 (IL-6)</subject><subject>Interleukin-6 - blood</subject><subject>Lipopolysaccharide Receptors - blood</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>pentraxin 3</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Protein-Energy Malnutrition - blood</subject><subject>protein-energy wasting</subject><subject>Renal Dialysis</subject><subject>Renal Insufficiency - blood</subject><subject>Renal Insufficiency - mortality</subject><subject>Renal Insufficiency - therapy</subject><subject>Serum Amyloid P-Component - metabolism</subject><subject>Survival Rate</subject><subject>Sweden</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kk1v1DAQhiMEokvhD3BAuSAuTfBHYscSqlQtH620iEoFcbS89qQ468TFThbtv8fRRoVy4GDZmnnmnZHfybKXGJUY1fRtV6puZ0qCkCgRKxEhj7IVrgktWEObx9kKEU4KRht2kj2LsUMJpIw9zU6w4JSKqlll32-8m7YO8vV7XOUb2IOLZ_nVMEJwMO3skLOzXA0m_-zDqJwdD_lF74fb_DrAXjkYxvwSem-scodoY36tRpuC8Xn2pFUuwovlPs2-ffzwdX1ZbL58ulpfbApdcz4WHFO-1dToVmjKhICq4qjd1oRzQ0SNiSIV19igSlEiRMM45016YyEMEKHoaVYcdeMvuJu28i7YXoWD9MrKJbRLL5B1zVBFEn9-5FOmB6PTrEG5B2UPM4P9IW_9XhLecFE3SeDNIhD8zwniKHsbNTinBvBTlOljGUpnbkWOpA4-xgDtfReM5Gyg7ORsoJwNlIjJZGAqevX3fH9KFscS8HoBVNTKtUEN2sZ7jhDcCCbqxL07cslQ2FsIMurkjAZjA-hRGm__P8f5P-Xa2cGmjjs4QOz8FIbkq8QyEonkzbxq86YhkUQq1NDfRFbOKg</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Raj, Dominic S.C., MD</creator><creator>Carrero, Juan J., PhD</creator><creator>Shah, Vallabh O., PhD</creator><creator>Qureshi, Abdul R., MD</creator><creator>Bárány, Peter, MD</creator><creator>Heimbürger, Olof, MD</creator><creator>Lindholm, Bengt, MD</creator><creator>Ferguson, Jennet, BA</creator><creator>Moseley, Pope L., MD</creator><creator>Stenvinkel, Peter, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20091201</creationdate><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><author>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>C-reactive protein (CRP)</topic><topic>C-Reactive Protein - metabolism</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Endotoxin</topic><topic>Endotoxins - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>hemodialysis</topic><topic>Humans</topic><topic>Inflammation - blood</topic><topic>Intensive care medicine</topic><topic>interleukin 6 (IL-6)</topic><topic>Interleukin-6 - blood</topic><topic>Lipopolysaccharide Receptors - blood</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>pentraxin 3</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Protein-Energy Malnutrition - blood</topic><topic>protein-energy wasting</topic><topic>Renal Dialysis</topic><topic>Renal Insufficiency - blood</topic><topic>Renal Insufficiency - mortality</topic><topic>Renal Insufficiency - therapy</topic><topic>Serum Amyloid P-Component - metabolism</topic><topic>Survival Rate</topic><topic>Sweden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raj, Dominic S.C., MD</creatorcontrib><creatorcontrib>Carrero, Juan J., PhD</creatorcontrib><creatorcontrib>Shah, Vallabh O., PhD</creatorcontrib><creatorcontrib>Qureshi, Abdul R., MD</creatorcontrib><creatorcontrib>Bárány, Peter, MD</creatorcontrib><creatorcontrib>Heimbürger, Olof, MD</creatorcontrib><creatorcontrib>Lindholm, Bengt, MD</creatorcontrib><creatorcontrib>Ferguson, Jennet, BA</creatorcontrib><creatorcontrib>Moseley, Pope L., MD</creatorcontrib><creatorcontrib>Stenvinkel, Peter, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raj, Dominic S.C., MD</au><au>Carrero, Juan J., PhD</au><au>Shah, Vallabh O., PhD</au><au>Qureshi, Abdul R., MD</au><au>Bárány, Peter, MD</au><au>Heimbürger, Olof, MD</au><au>Lindholm, Bengt, MD</au><au>Ferguson, Jennet, BA</au><au>Moseley, Pope L., MD</au><au>Stenvinkel, Peter, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>54</volume><issue>6</issue><spage>1072</spage><epage>1080</epage><pages>1072-1080</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting &amp; Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19733948</pmid><doi>10.1053/j.ajkd.2009.06.022</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2009-12, Vol.54 (6), p.1072-1080
issn 0272-6386
1523-6838
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_556042
source MEDLINE; Elsevier ScienceDirect Journals; SWEPUB Freely available online
subjects Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Biomarkers - blood
C-reactive protein (CRP)
C-Reactive Protein - metabolism
Emergency and intensive care: renal failure. Dialysis management
Endotoxin
Endotoxins - blood
Female
Follow-Up Studies
hemodialysis
Humans
Inflammation - blood
Intensive care medicine
interleukin 6 (IL-6)
Interleukin-6 - blood
Lipopolysaccharide Receptors - blood
Longitudinal Studies
Male
Medical sciences
Middle Aged
Nephrology
Nephrology. Urinary tract diseases
pentraxin 3
Predictive Value of Tests
Prospective Studies
Protein-Energy Malnutrition - blood
protein-energy wasting
Renal Dialysis
Renal Insufficiency - blood
Renal Insufficiency - mortality
Renal Insufficiency - therapy
Serum Amyloid P-Component - metabolism
Survival Rate
Sweden
title Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A19%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20CD14%20Levels,%20Interleukin%206,%20and%20Mortality%20Among%20Prevalent%20Hemodialysis%20Patients&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Raj,%20Dominic%20S.C.,%20MD&rft.date=2009-12-01&rft.volume=54&rft.issue=6&rft.spage=1072&rft.epage=1080&rft.pages=1072-1080&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2009.06.022&rft_dat=%3Cproquest_swepu%3E733603362%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733603362&rft_id=info:pmid/19733948&rft_els_id=S0272638609009408&rfr_iscdi=true